A few recent fragments
How can you proactively scan, adapt, and act?
Here’s a small collection of moments, sketches, or ideas. Some finished, some still figuring themselves out.
See the Fast Five #2
Expand due diligence in line with changing risks.
-
+
Due diligence will always be critical to transaction success. Decision-makers may want to take a different view of diligence in today’s context and expand the scope of what they’ve explored in the past. For instance, data sovereignty will be increasingly important from here on out, particularly in this sector where confidential health data abounds. That’s in addition to more traditional due diligence areas (for example, ensuring policies and procedures are in place to maintain security, verifying manufacturing practices, assessing supply chain exposure, etc.).
Focus on data integrity across its lifecycle.
-
+
Within the organization, who owns data? Is it collected properly? Does the target have lawful authority to use it for the intended purposes? Is the acquisition target taking appropriate steps to ensure cross-border transmission is permitted? These kinds of questions are crucial to identifying potential exposures and possible compliance issues before the deal is done.
Consider indemnities in situations where the company is not up to date on risk management.
-
+
Depending on the maturity of the business and the nature of its pharma or life sciences operations, companies will have varying degrees of sophistication in terms of risk management. In some cases, investors will want to secure an indemnity with the founder, to back the business and potential risks, in order to mitigate potential downsides.
Ensure business practices evolve with the law.
-
+
This will reduce exposure to claims, while fostering the kind of goodwill and business opportunities industry leaders value.